Prestige Consumer Healthcare Inc. Common Stock (PBH)
Stock · NYSE · Health Care
$49.93as of 10/16/2026
Price chart
Active signals
PBH Signal Track Record
How signals performed across all stocks →What PBH's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 27 | -0.1% | 48% | September 18, 2026 |
| Bollinger Band Breakdown | 26 | -0.9% | 42% | September 9, 2026 |
| Bollinger Band Breakout | 23 | +0.8% | 52% | July 28, 2026 |
| 200-Day Moving Average TouchActive now | 22 | +1.4% | 50% | February 19, 2026 |
| Any 20-session window (baseline) | -0.2% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PBH
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatmen…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 890
- Website
- www.prestigebrands.com/
Fundamentals
- 1-day range
- $49.28$50.27
- Market cap
- $2.58B
- P/E (trailing)
- 13.50
- P/E (forward)
- 9.79
- EPS (trailing)
- $3.57
- Dividend yield
- —
- Beta
- 0.31
- Avg. volume
- 554.2K
- Ex-dividend date
- December 27, 2013
How Prestige Consumer Healthcare Inc. Common Stock Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed May 14, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Prestige Consumer Healthcare Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PBHPrestige Consumer Healthcare Inc. Common Stock$49.92▲ 1.46%Market cap $2.58BP/E 13.50$42.62$71.07
- RAREUltragenyx Pharmaceutical Inc. Common Stock$14.54▼ 4.15%Market cap $2.54BP/E —$12.73$39.89
- NRIXNurix Therapeutics Inc. Common stock$24.42▼ 2.12%Market cap $2.62BP/E 9.25$9.14$28.23
- TRVITrevi Therapeutics Inc. Common Stock$11.88▼ 1.90%Market cap $2.63BP/E —$9.28$20.22
- NKTRNektar Therapeutics Common Stock$35.78▼ 5.14%Market cap $2.48BP/E —$33.4$109
- PGENPrecigen Inc. Common Stock$6.39▼ 11.25%Market cap $2.47BP/E —$3.04$8.98
- AMLXAmylyx Pharmaceuticals Inc. Common Stock$26.34▼ 4.74%Market cap $2.69BP/E —$10.83$41.14
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PBH Prestige Consumer Healthcare Inc. Common Stock | $2.58B | 13.50 | $49.92 | ▲ 1.46% | $42.62$71.07 |
| RARE Ultragenyx Pharmaceutical Inc. Common Stock | $2.54B | — | $14.54 | ▼ 4.15% | $12.73$39.89 |
| NRIX Nurix Therapeutics Inc. Common stock | $2.62B | 9.25 | $24.42 | ▼ 2.12% | $9.14$28.23 |
| TRVI Trevi Therapeutics Inc. Common Stock | $2.63B | — | $11.88 | ▼ 1.90% | $9.28$20.22 |
| NKTR Nektar Therapeutics Common Stock | $2.48B | — | $35.78 | ▼ 5.14% | $33.4$109 |
| PGEN Precigen Inc. Common Stock | $2.47B | — | $6.39 | ▼ 11.25% | $3.04$8.98 |
| AMLX Amylyx Pharmaceuticals Inc. Common Stock | $2.69B | — | $26.34 | ▼ 4.74% | $10.83$41.14 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Transcript: Prestige Consumer Q1 2027 Earnings Conference Callbenzinga · 10/7/2026
- Transcript: Prestige Consumer Q1 2027 Earnings Conference CallBenzinga · 10/7/2026
- Best Value Stocks to Buy for October 1stYahoo · 10/1/2026
- PBH vs. NEOG: Which Stock Is the Better Value Option?Yahoo · 9/30/2026
- More Than Half of U.S. Women Have Avoided Talking About an Intimate Wellness Concern Because They Felt Embarrassed or Uncomfortable, New Summer's Eve® Survey FindsYahoo · 9/30/2026
- Has Prestige Consumer Healthcare (PBH) Fallen Far Enough On Earnings?Yahoo · 9/29/2026
- Prestige Consumer Healthcare (PBH) Could Be 30% Undervalued After Its 2027 TargetsYahoo · 9/29/2026
- Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash FlowYahoo · 9/27/2026
- PBH or NEOG: Which Is the Better Value Stock Right Now?Yahoo · 9/14/2026
Insider Activity
Insider Actions →- Dawn M. Zier · August 4, 2026 · Grant3.0K
- Kelly John F. · August 4, 2026 · Grant3.0K
- James DArecca · August 4, 2026 · Grant3.0K
- Celeste A. Clark · August 4, 2026 · Grant3.0K
- BYOM JOHN E · August 4, 2026 · Grant3.0K
- Zerillo Jeffrey · May 11, 2026 · Sale351 @ $52.28
- Zerillo Jeffrey · May 7, 2026 · Sale305 @ $54.36
- Zerillo Jeffrey · May 7, 2026 · Tax Withholding351 @ $54.59
- Sacco Christine · May 7, 2026 · Tax Withholding991 @ $54.59
- Lombardi Ronald M. · May 7, 2026 · Tax Withholding2.5K @ $54.59
- Mekhail Adel · May 7, 2026 · Tax Withholding487 @ $54.59
- Zerillo Jeffrey · May 5, 2026 · Sale1.2K @ $54.99
- Zerillo Jeffrey · May 5, 2026 · Tax Withholding307 @ $55.75
- Sacco Christine · May 5, 2026 · Tax Withholding1.3K @ $55.75
- Lombardi Ronald M. · May 5, 2026 · Tax Withholding2.2K @ $55.75
Institutional Ownership
March 31, 2026
- Total shares held
- 48.28M
- Total value held
- $2.77B
- Institutional holders
- 342
- Unknown7.39M
- Unknown4.27M
- Unknown2.67M
- Unknown2.20M
- Unknown2.09M
- Unknown1.97M
- Unknown1.56M
- Unknown1.46M
- Unknown1.36M
- Unknown1.12M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Prestige Consumer Healthcare Reports Q1 2027 Earnings
Prestige Consumer Healthcare released the transcript of its Q1 2027 earnings call. The company discussed its quarterly results and outlook, providing detailed guidance on revenue, earnings, and future plans. The release offers investors a clearer view of the company's performance and strategy.
Prestige Consumer Healthcare Reports Q1 2027 Earnings. Prestige Consumer Healthcare released the transcript of its Q1 2027 earnings call. The company discussed its quarterly results and outlook, providing detailed guidance on revenue, earnings, and future plans. The release offers investors a clearer view of the company's performance and strategy.